Ann: Clinical Study Result , page-20

My rough calcs based on 40% for next 3 years - we should be so lucky

Year Dose Sales Sales Market Pen%
2011/2 6140 $92,100,000 0.7
1 8596 $128,940,000 1.0
2 12034 $180,516,000 1.4
3 16848 $252,722,400 1.9

Based on profit increasing 20% more that dose sales (on an 80% gross this I think is reasonable), the figures came out at..
Share Price Profit M$
8 $22,000,000
14 $36,960,000
23 $62,092,800
39 $104,315,904

Is 17000 doses achievable in 3 years - I think so, and indeed may be some way above.

This is pure conjecture!


Maybe a lot too optimistic, but one has to start somewhere and work back from a future value.